Cargando…

Anemia is a poor prognostic factor for stage I non-small cell lung cancer (NSCLC) patients treated with Stereotactic Body Radiation Therapy (SBRT)

• This study reports on the prognostic ability of haematological parameters for the largest known biopsy-proven stage-I medically inoperable cohort treated with SBRT. • After SBRT, the median values of Hb, ALC, ANC and TPC declined whereas the NLR and the PLR increased as compared to pre-SBRT. • Ane...

Descripción completa

Detalles Bibliográficos
Autores principales: Pathak, Rima S., Pantarotto, Jason R., Cook, Graham, Holmes, Oliver, Cross, Peter, MacRae, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423348/
https://www.ncbi.nlm.nih.gov/pubmed/30923751
http://dx.doi.org/10.1016/j.ctro.2019.01.003
Descripción
Sumario:• This study reports on the prognostic ability of haematological parameters for the largest known biopsy-proven stage-I medically inoperable cohort treated with SBRT. • After SBRT, the median values of Hb, ALC, ANC and TPC declined whereas the NLR and the PLR increased as compared to pre-SBRT. • Anemia along with other parameters was found to be a poor prognostic factor for local control despite treatment with SBRT to doses of >100 Gy BED(10). • Simple and minimally invasive methods like a peripheral blood sample can provide prognostic information even for stage-I NSCLC patients. • Patient, tumor and treatment factors along with molecular markers should be used to create risk stratification models that can guide therapy.